Major Nasal Decongestant

Description

Oxymetazoline Hydrochloride is a nasal decongestant formulated at a concentration of 0.05%. It is presented as a 12-hour nasal mist, designed for the relief of nasal congestion. The product is contained in a 1/2 fluid ounce (15 mL) bottle, suitable for topical administration in the nasal cavity.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, sinusitis, and upper respiratory allergies. It functions by shrinking swollen nasal membranes, thereby facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 6 to under 12 years, the recommended dosage is 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period.

For children under 6 years of age, it is advised to consult a physician prior to administration.

To properly administer the spray, the healthcare professional should instruct the patient to squeeze the bottle quickly and firmly. The patient should avoid tilting their head backward during the spraying process. After use, the nozzle should be wiped clean to maintain hygiene and prevent blockage.

Contraindications

Use is contraindicated in the following situations:

• Use is not recommended for more than three consecutive days, as frequent or prolonged use may lead to the recurrence or worsening of nasal congestion.

• The product should not be used by more than one person, as this may facilitate the spread of infection.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product.

General precautions must be strictly adhered to in order to ensure safe usage. It is imperative that the product is not used in excess of the directed dosage. Additionally, the product should not be utilized for more than three consecutive days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion. Users may experience temporary discomfort, which can include symptoms such as burning, stinging, sneezing, or an increase in nasal discharge. Furthermore, it is important to note that sharing this container among multiple individuals may facilitate the spread of infection.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Healthcare professionals are advised to instruct patients to discontinue use and consult a physician if symptoms persist. This precaution is essential to ensure that any underlying conditions are appropriately addressed.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. It is important to consult a healthcare professional before use, particularly for individuals with pre-existing conditions such as heart disease, high blood pressure, diabetes, thyroid disease, or those experiencing trouble urinating due to an enlarged prostate gland.

While specific adverse reactions have not been detailed in the provided information, the presence of warnings suggests that serious reactions may occur. Therefore, monitoring for any unusual symptoms or changes in health status is advised during treatment.

In clinical practice, it is essential for healthcare providers to evaluate the risk-benefit profile for each patient, especially those with the aforementioned conditions, to ensure safe and effective use of the medication.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Major Nasal Decongestant (oxymetazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important to note that the total dosage should not exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with its use during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific information regarding overdosage in the provided sections of the Summary of Product Characteristics (SPL), healthcare professionals are advised to exercise caution and consider general principles of management for suspected overdosage.

Recommended Actions In the event of an overdosage, it is essential for healthcare providers to assess the patient's clinical status and initiate appropriate supportive care. Monitoring of vital signs and symptomatic treatment should be prioritized.

Potential Symptoms While specific symptoms of overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise, given the variability in individual responses to medications.

Management Procedures Healthcare professionals are encouraged to consult local poison control centers or relevant toxicology resources for guidance on the management of suspected overdosage cases. It is critical to document all findings and interventions thoroughly to ensure continuity of care and facilitate further evaluation if necessary.

In summary, due to the lack of specific overdosage information, a cautious and supportive approach is recommended, with an emphasis on monitoring and symptomatic management.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients to discontinue use and consult a doctor if symptoms persist. Patients should be cautioned against exceeding the recommended dosage and should not use the product for more than three consecutive days. Emphasize that frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. Providers should inform patients that sharing this container with others may pose a risk of spreading infection.

Additionally, healthcare providers should recommend that patients consult a doctor prior to use if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers, which should be retained for future reference regarding full labeling. It is essential to store the product at a temperature range of 20° to 25°C (68° to 77°F) to ensure its stability and efficacy. Additionally, the carton should be kept for future reference to access complete labeling information.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Major Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)